Climb Bio (CLYM) Common Equity (2020 - 2026)

Climb Bio has reported Common Equity for 7 years, with the latest figure at $148.1 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 23.42% year-over-year to $148.1 million; the trailing twelve-month figure through Mar 2026 stood at $148.1 million (down 23.42% YoY), and the FY2025 full-year result was $160.5 million, down 24.26% from the prior year.
• Common Equity for Q1 2026 stood at $148.1 million, down from $160.5 million in the prior quarter.
• The five-year high for Common Equity was $222.3 million in Q2 2024, with the low at $106.4 million in Q1 2024.
• Historically, Common Equity has averaged $154.8 million across 5 years, with a median of $148.1 million in 2026.
• Annual changes were most pronounced in 2022 — Common Equity jumped 459.27% — and 2023, when it dropped 24.68%.
• Climb Bio's Common Equity stood at $128.7 million in 2022, then dropped by 16.41% to $107.6 million in 2023, then surged by 96.92% to $211.9 million in 2024, then decreased by 24.26% to $160.5 million in 2025, then dropped by 7.72% to $148.1 million in 2026.
• The last three Common Equity figures came in at $148.1 million (Q1 2026), $160.5 million (Q4 2025), and $177.0 million (Q3 2025), per Business Quant data.